Ezetimibe and Injection site erythema - a phase IV clinical study of FDA data

Summary:

Injection site erythema is reported as a side effect among people who take Ezetimibe (ezetimibe), especially for people who are female, 60+ old, also take Repatha, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Injection site erythema when taking Ezetimibe. It is created by eHealthMe based on reports of 30,221 people who have side effects when taking Ezetimibe from the FDA, and is updated regularly.

What is Ezetimibe?

Ezetimibe has active ingredients of ezetimibe. It is often used in high blood cholesterol. eHealthMe is studying from 30,849 Ezetimibe users. Check the latest studies of Ezetimibe.

What is Injection site erythema?

Injection site erythema (redness at injection site) is found to be associated with 1,449 drugs and 1,417 conditions by eHealthMe. Check the latest studies of Injection site erythema.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

30,221 people reported to have side effects when taking Ezetimibe.
Among them, 66 people (0.22%) have Injection site erythema.

Could Ezetimibe cause Injection site erythema?

Among these 66 people:

What is the gender of people who have Injection site erythema when taking Ezetimibe? *

female: 79.66 %
male: 20.34 %

What is the age of people who have Injection site erythema when taking Ezetimibe? *

What are other drugs people take besides Ezetimibe? *

What are other side effects people have besides Injection site erythema? *

Injection Site Swelling: 32 people, 48.48%
Injection Site Pruritus (severe itching at injection site): 25 people, 37.88%
Injection Site Pain: 22 people, 33.33%
Injection Site Rash: 14 people, 21.21%
Rashes (redness): 11 people, 16.67%
Joint Pain: 10 people, 15.15%
Injection Site Reaction: 9 people, 13.64%
Headache (pain in head): 8 people, 12.12%
Fatigue (feeling of tiredness): 8 people, 12.12%
Injection Site Bruising: 7 people, 10.61%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 10 people, 15.15%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 7 people, 10.61%
Diabetes: 7 people, 10.61%
High Blood Pressure: 5 people, 7.58%
Sleep Disorder: 4 people, 6.06%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 6.06%
Hyperlipidaemia (presence of excess lipids in the blood): 4 people, 6.06%
Depression: 4 people, 6.06%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 4 people, 6.06%
Stress And Anxiety: 3 people, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Ezetimibe and have Injection site erythema?

- Check whether Injection site erythema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ezetimibe:

Ezetimibe (30,849 reports)

Browse all side effects of Ezetimibe:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site erythema:

Injection site erythema (1,449 drugs)

Browse all the conditions that are associated with Injection site erythema:

Injection site erythema (1,417 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ezetimibe (the active ingredients of Ezetimibe) and Ezetimibe (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.